Business, energy, technology, markets and global industry news from Business News Today

Johnson & Johnson Innovation

PharmaDeviceNews Johnson & Johnson Innovation
Sail Biomedicines’ in vivo CAR-T collaboration with Johnson & Johnson highlights growing investment in RNA-based immune-cell therapies for autoimmune diseases. Representative image.
Pharma & Biotech

Why Johnson & Johnson is staking $785m on Sail’s in vivo CAR-T platform before human trials

Johnson & Johnson backs Sail Biomedicines’ in vivo CAR-T platform with $785 million in initial payments and a $2.58 billion buyout option.

Read More
Representative image of a neurology consultation for normal pressure hydrocephalus, illustrating how CereVasc’s eShunt System could advance minimally invasive treatment beyond traditional shunt surgery.
Medical Devices & Diagnostics

Can CereVasc’s $85m raise move hydrocephalus treatment beyond traditional shunt surgery?

CereVasc’s $85m raise backs eShunt, a minimally invasive hydrocephalus device. The STRIDE trial now carries the real test.

Read More
Pharma & Biotech

Resolve M Therapeutics exits stealth with Johnson & Johnson Innovation support to pursue MS1-driven immune resolution

Resolve M exits stealth with a bold MS1-based approach to inflammation. Learn how its pro-resolution platform could reshape autoimmune drug development.

Read More